Kengreal, Kengrexal(cangrelor)
Kengreal, Kengrexal (cangrelor) is a small molecule pharmaceutical. Cangrelor was first approved as Kengrexal on 2015-03-23. It has been approved in Europe to treat acute coronary syndrome and vascular surgical procedures. The pharmaceutical is active against P2Y purinoceptor 12. In addition, it is known to target uracil nucleotide/cysteinyl leukotriene receptor and P2Y purinoceptor 13.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| cardiovascular diseases | D002318 |
| operative surgical procedures | D013514 |
Trade Name
FDA
EMA
Kengreal
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Cangrelor
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| KENGREAL | Chiesi Farmaceutici | N-204958 RX | 2015-06-22 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| kengreal | New Drug Application | 2022-09-06 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
HCPCS
Code | Description |
|---|---|
| C9460 | Injection, cangrelor, 1 mg |
| G9531 | Patient has documentation of ventricular shunt, brain tumor, multisystem trauma, or is currently taking an antiplatelet medication including: abciximab, anagrelide, cangrelor, cilostazol, clopidogrel, dipyridamole, eptifibatide, prasugrel, ticlopidine, ticagrelor, tirofiban, or vorapaxar |
Clinical
Clinical Trials
41 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myocardial infarction | D009203 | EFO_0000612 | I21 | — | — | 1 | 7 | 6 | 14 |
| Infarction | D007238 | EFO_0009463 | — | — | — | 1 | 7 | 6 | 14 |
| Coronary artery disease | D003324 | — | I25.1 | — | 3 | — | 4 | 5 | 12 |
| Acute coronary syndrome | D054058 | EFO_0005672 | — | — | 1 | 3 | 5 | 2 | 11 |
| St elevation myocardial infarction | D000072657 | — | — | — | 1 | — | 7 | 1 | 9 |
| Heart arrest | D006323 | EFO_0009492 | I46 | — | — | — | 2 | 1 | 3 |
| Percutaneous coronary intervention | D062645 | — | — | — | — | 1 | 1 | 1 | 3 |
| Inferior wall myocardial infarction | D056989 | EFO_1000983 | — | — | — | — | 1 | 2 | 3 |
| Syndrome | D013577 | — | — | — | — | — | 1 | 1 | 2 |
| Cardiogenic shock | D012770 | — | R57.0 | — | — | — | 1 | 1 | 2 |
Show 5 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Stroke | D020521 | EFO_0000712 | I63.9 | — | — | 2 | — | — | 2 |
| Atherosclerosis | D050197 | EFO_0003914 | I25.1 | — | — | 2 | — | — | 2 |
| Ischemia | D007511 | EFO_0000556 | — | — | — | 1 | — | — | 1 |
| Ischemic stroke | D000083242 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Coronary disease | D003327 | — | — | — | 3 | — | — | 3 | 6 |
| Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | — | 3 | — | — | 3 | 6 |
| Stable angina | D060050 | — | I20.89 | — | 1 | — | — | — | 1 |
| Reperfusion injury | D015427 | — | — | — | 1 | — | — | — | 1 |
| Platelet aggregation | D010974 | GO_0070527 | — | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 2 | — | — | — | — | 2 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Covid-19 | D000086382 | — | — | — | — | — | — | 1 | 1 |
| Non-st elevated myocardial infarction | D000072658 | — | — | — | — | — | — | 1 | 1 |
| Hemorrhage | D006470 | MP_0001914 | R58 | — | — | — | — | 1 | 1 |
| Heart diseases | D006331 | EFO_0003777 | I51.9 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Cangrelor |
| INN | cangrelor |
| Description | Cangrelor is a nucleoside triphosphate analogue that is 5'-O-[({[dichloro(phosphono)methyl](hydroxy)phosphoryl}oxy)(hydroxy)phosphoryl]adenosine carrying additional 2-(methylsulfanyl)ethyl and (3,3,3-trifluoropropyl)sulfanyl substituents at positions N6 and C2 respectively. Used (in the form of its tetrasodium salt) as an intravenous antiplatelet drug that prevents formation of harmful blood clots in the coronary arteries. It has a role as a platelet aggregation inhibitor and a P2Y12 receptor antagonist. It is a nucleoside triphosphate analogue, an organofluorine compound, an aryl sulfide, an organochlorine compound, a secondary amino compound and an adenosine 5'-phosphate. It is a conjugate acid of a cangrelor(4-). |
| Classification | Small molecule |
| Drug class | platelet aggregation inhibitors, primarily platelet P2Y12 receptor antagonists |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CSCCNc1nc(SCCC(F)(F)F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)C(Cl)(Cl)P(=O)(O)O)[C@@H](O)[C@H]1O |
Identifiers
| PDB | — |
| CAS-ID | 163706-06-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL334966 |
| ChEBI ID | — |
| PubChem CID | 9854012 |
| DrugBank | DB06441 |
| UNII ID | 6AQ1Y404U7 (ChemIDplus, GSRS) |
Target
Agency Approved
P2RY12
P2RY12
Organism
Homo sapiens
Gene name
P2RY12
Gene synonyms
HORK3
NCBI Gene ID
Protein name
P2Y purinoceptor 12
Protein synonyms
ADP-glucose receptor, ADPG-R, G-protein coupled receptor SP1999, Gi-coupled ADP receptor HORK3, P2T(AC), P2Y(AC), P2Y(ADP), P2Y(cyc), P2Y12 platelet ADP receptor, purinergic receptor P2RY12, purinergic receptor P2Y, G-protein coupled, 12, putative G-protein coupled receptor, SP1999
Uniprot ID
Mouse ortholog
P2ry12 (70839)
P2Y purinoceptor 12 (Q9CPV9)
Alternate
GPR17
GPR17
P2RY13
P2RY13
Organism
Homo sapiens
Gene name
GPR17
Gene synonyms
NCBI Gene ID
Protein name
uracil nucleotide/cysteinyl leukotriene receptor
Protein synonyms
G-protein coupled receptor 17, P2Y-like receptor, R12, UDP/CysLT receptor
Uniprot ID
Mouse ortholog
Gpr17 (574402)
uracil nucleotide/cysteinyl leukotriene receptor (Q80UD2)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,442 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
312 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use